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The aim of this study was to evaluate the eﬀe c to fa ne t h a n o le x t r a c to ft h er h i z o m e so fDioscorea alata L. cv. Phyto, Dispo85E,
on bone formation and to investigate the mechanisms involved. Our results showed that Dispo85E increased the activity of
alkaline phosphatase (ALP) and bone nodule formation in primary bone marrow cultures. In addition, Dispo85E stimulated
pluripotentC3H10T1/2stemcellstodiﬀerentiateintoosteoblastsratherthanadipocytes.Our invivodataindicatedthatDispo85E
promotesosteoblastogenesisbyincreasingALPactivityandbonenoduleformationinbothintactandovariectomized(OVX)mice.
Microcomputed tomography (μCT) analysis also showed that Dispo85E ameliorates the deterioration of trabecular bone mineral
density (tBMD), trabecular bone volume/total volume (BV/TV), and trabecular bone number (Tb.N) in OVX mice. Our results
suggestedthatDispo85Eisabotanicaldrugwithanovelmechanismthatdrivesthelineage-speciﬁcdiﬀerentiationofbonemarrow
stromal cells and is a candidate drug for osteoporosis therapy.
1.Introduction
Osteoporosis is a prevalent bone disease that is deﬁned by
a low bone mass and an increased risk of fractures [1].
Adequate regulation of bone remodeling in adulthood is
essential to maintain a healthy bone mass [2]. However,
an imbalance between bone formation and bone resorption
in pathological conditions or during the aging process can
result in conditions that lead to osteoporosis [3]. In the past,
the process of bone remodeling was considered to be regu-
lated by two major cell types: bone-forming osteoblasts and
bone-resorbing osteoclasts [4]. Currently available agents
used to treat osteoporosis include estrogen, raloxifene, the
bisphosphonates (e.g., alendronate and risedronate, etc.),
andcalcitonin.Theirmechanismsarebasedontheinhibition
of osteoclastic bone resorption to prevent further bone loss
[5]. However, many osteoporotic patients already had lost
a substantial amount of bone mass before diagnosis [6].
Furthermore, many side eﬀects of antiresorptive agents have
been reported, causing many patients to discontinue their
use [7–9].
Drugs with anabolic eﬀects have received much recent
attention for osteoporosis therapy. These pharmacologic
agents can ultimately stimulate new bone formation, en-
hance bone density, reduce bone fracture, and promote bone
health. Currently, there is only one available anabolic agent
on the market approved for the treatment of osteoporosis,
recombinant human parathyroid hormone (hPTH). How-
ever, hPTH is limited for use in cases of severe osteoporosis
[10], and the clinical treatment period is limited to 18
months [11]. Consequently, it is necessary to develop other
potential anabolic agents with fewer undesirable side eﬀects
to prevent or reverse osteoporosis.
The Chinese yam (Dioscorea) has been widely used as a
herbal medicine in China for more than 2000 years. Ancient
Chinese medicinal books or folk remedies have provided
evidence that Dioscorea might have eﬀects in regulating bone
metabolism. Therefore, we initiated a project to evaluate2 Evidence-Based Complementary and Alternative Medicine
the eﬀects of an ethanol extract of rhizomes of Dioscorea
alataL.cv.Phyto,Dispo85E,onboneformationandtodelin-
eate the mechanisms involved. In our study, we found that
Dispo85E promoted bone formation by inducing mesenchy-
mal stem cells (MSCs) diﬀerentiation into osteoblasts rather
than adipocytes and that it also possessed antiosteoporotic
activity in vivo.
2.MaterialsandMethods
2.1. Animals. Speciﬁc pathogen-free (SPF) C57BL/6 female
m i c e ,8t o1 0w e e k so fa g e ,w e r eo b t a i n e df r o mt h eN a t i o n a l
Laboratory Animal Center (Taipei, Taiwan). Animals were
housed at a constant temperature and fed with laboratory
chow (PMI, Brentwood, Mo, USA) and water ad libitum.
The protocol of the experiments was approved by the
Animal Research Committee of National Yang-Ming Uni-
versity (Guide for Animal Experiments, National Yang-Ming
University).
2.2. Preparation of Dispo85E. Dried and peeled tubers
of Dioscorea alata L. cv. Phyto (2.92kg) were extracted
with 85% ethanol (EtOH) (15L each, three times) for 24
hours. The extract was ﬁltered through an 11μmW h a t m a n
ﬁlter, then concentrated under vacuum evaporator and
lyophilized, giving a yield of 3.05%. The extract was stored
at −20◦C before use.
2.3. HPLC Analysis of Dispo85E. Twenty milligrams of dried
Dispo85Ewasdissolvedin2mLofdichloromethane(DCM).
After centrifugation, the supernatant was evaporated to dry-
ness, adjusted to a concentration of 5mg/mL in DCM and
then subjected to normal-phase high performance liquid
chromatography (NP-HPLC) with a 100μL injection vol-
ume. The pellet was evaporated to dryness, adjusted to a
concentration of 10mg/mL in water and then subjected to
reverse-phasehighperformanceliquidchromatography(RP-
HPLC) with a 100μL injection volume. RP-HPLC proﬁling
was performed using a Mightysil RP-18 column (4.6 ×
250mm, 5mm) at room temperature. The mobile phase was
methanol and water in gradient mode (10:90–100:0 over
120 minutes). The eﬄuent was monitored at 254nm, and
a constant ﬂow rate was set at 0.8mL/minute. NP-HPLC
proﬁling was performed with a Cosmosil 5SL-II column
(4.6 × 250mm, 5mm) at room temperature. The mobile
phase was DCM and methanol (MeOH) in gradient mode
as follows: 100%–98% DCM in MeOH (0–15 minutes),
98%-95% DCM (15–25 minutes), 95%–90% DCM (25–
35 minutes), 90%–80% DCM (35–45 minutes), and 80%–
70% DCM (45–55 minutes). The eﬄuent was monitored at
254nm, and a constant ﬂow rate was set at 0.8mL/minute.
2.4. Cell Culture. Primary mouse bone marrow cells and
C3H10T1/2 cells were cultured as described previously [12,
13]. Brieﬂy, bone marrow cells were obtained from the
femoral bone of SPF-grade C57BL/6 female mice. The bone
marrow cells were collected by ﬂushing the diaphysis with α-
minimum essential medium (α-MEM, Gibco BRL) through
a 23-gauge needle. After ﬂushing, the bone marrow cells
were ﬁltered through a no. 53 sterile nylon mesh to obtain
a single cell suspension. The cells were cultured in osteogenic
medium(α-MEMmediumsupplementedwith15%fetalcalf
serum(FCS, Gibco), 50μg/mL ascorbicacid (Sigma),10mm
sodium β-glycerophosphate (Sigma), and 10nm dexametha-
sone (Sigma)). The pluripotent murine mesenchymal cell
line C3H10T1/2 was cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FCS.
For the alkaline phosphatase (ALP) activity assay, pri-
mary bone marrow cells were seeded in a 96-well microplate
at 2.5 × 105/well and cultured in osteogenic induction me-
dium. After two days, half of the medium was changed and
the cells were incubated with Dispo85E at the indicated con-
centrations for 4 days. ALP activity for each cell lysate was
assayed. C3H10T1/2 cells were grown to conﬂuence in stan-
dard medium. One day afterthe cells reached conﬂuence, the
medium was replaced with permissive osteogenic/adipocytic
medium [14] (DMEM with 10% FCS, 50μg/mL ascorbic
acid, 10μMs o d i u mβ-glycerophosphate, 10nm dexameth-
asone, 10nm all-trans retinoic acid (Sigma), 10μg/mL in-
sulin (Sigma), and 50μM isobutylmethylxanthine (IBMX,
Sigma)) containing drugs at the indicated concentrations.
The medium was changed every 4 days. After 12 days, ALP
activity for each cell lysate was assayed.
For the nodule formation assay, primary bone marrow
cells were seeded in a 24-well microplate at 1 × 106/well
and cultured in osteogenic induction medium. After two
days, half of the medium was changed and the cells were
incubated with Dispo85E at the indicated concentrations.
Theculturemediumwasrenewedevery4days.After14days,
the mineralization of bone marrow cells was analyzed.
For lipid staining, C3H10T1/2 cells were grown to con-
ﬂuence in standard medium. One day after the cells reached
conﬂuence, the medium was replaced with adipogenic me-
dium (DMEM with 10% FCS, 10μg/mL insulin, 1μMd e x -
amethasone, and 0.5mm IBMX) containing drugs at the
indicated concentrations for 4 days. The cells were then
incubated in a standard medium containing 5μg/mL insulin
and drugs at the indicated concentrations. The medium
was changed every 4 days. The oil red O staining was
performed at postinduction day (PID) 12. Nile red staining
was performed at PID16.
2.5. Alkaline Phosphatase Activity Assay. ALP activity was
assayed at 37◦C by a method modiﬁed from that of Qu
et al. [15]. In brief, cell layers were washed twice with
phosphate buﬀered saline (PBS) and extracted into lysis
solution (10mm Tris, 0.1% Triton X-100 buﬀer (pH 7.5)).
Enzyme activity was determined colorimetrically using p-
nitrophenylphosphate (p-NPP, Sigma) as a substrate. The
reaction mixture contained 8mm p-NPP, 2mmmgCl2,
and 0.5M 2-amino-2-methyl-1-propanol, pH 10. After 10
minutes of incubation, the color change of p-NPP to p-
nitrophenol was monitored at 405nm. Cell viability was
determined by resazurin assay. Fifty micromolar resazurin
(Sigma) was added to the cell culture medium and incubated
for 2 hours. Medium samples were collected into a 96-wellEvidence-Based Complementary and Alternative Medicine 3
plate, and ﬂuorescence was measured with excitation at
544nm and emission at 590nm.
2.6. Nodule Formation Assay. The in vitro mineralized nod-
ule formation assay was performed as described previously
[16]. In brief, cells were ﬁxed with 10% formalin for 30
m i n u t e sa t3 7 ◦C. The formalin was removed, and the cells
rinsed with sterilized water three times. Next, 2% alizarin
red S solution, which reacts with calcium, was added to the
wells and the cells were incubated at 37◦Cf o r1 0m i n u t e s .
The Alizarin solution was removed, and the cells were
washed with water and dried in air. Stained cultures were
photographed, and calcium deposition was quantiﬁed by
extracting alizarin red S staining with 10% cetylpyridinium
chloride (CPC, Sigma) and measuring the OD of the extract
at 550nm [17].
2.7. Adipocyte Staining with Oil Red O. After diﬀerentiation
was induced, cells were stained with oil red O. Brieﬂy, cells
were washed twice with PBS and ﬁxed with 10% formalin
in PBS for 1 hour. They were then washed three times with
water. Cells were stained with Oil Red O (six parts of 0.6%
oil red O dye (Sigma-Aldrich) in isopropanol and four
parts of water) for 30 minutes. Excess stain was removed
by washing with water, and the stained cells were dried.
Adipocytes stained red were observed under the phase
contrast microscope with 200-fold magniﬁcation.
2.8. Quantiﬁcation of Adipocyte Number by Flow Cytometry.
Theformationofmatureadipocyteswasquantiﬁedwithﬂow
cytometry using the lipophilic Nile red ﬂuorescent dye as
describedpreviously[18].Brieﬂy,afterthecellswereinduced
to diﬀerentiate into adipocytes as indicated above, they were
washed twice in PBS, trypsinized, pelleted by centrifugation,
a n dﬁ x e di n1 0 %f o r m a l d e h y d ef o r1 ha t4 ◦C. A working
solution of Nile red was prepared by dissolving 1mg Nile red
in 200μL DMSO and diluting to 100mL with PBS. The cells
were stained with 10μg/mL Nile red for 45 minutes at room
temperature. The ﬂuorescent emission was detected between
564nm and 604nm with a band-pass ﬁlter using a FACScan
ﬂow cytometer (BD Biosciences) linked with Cell-Quest 3.3
software (BD Biosciences).
2.9. Isolation and Analysis of RNA. T o t a lR N Aw a se x t r a c t e d
from the bone marrow cells using the Ultraspec RNA iso-
lation kit (Biotex laboratories INC, USA). RNA was reverse
transcribed using AMV reverse transcriptase (Promega,
USA) and an appropriate buﬀer in a ﬁnal reaction vol-
ume of 40μL. The complementary DNA (cDNA) was ob-
tained using the previous reaction solution at 42◦Cf o r6 0
minutes, followed by 90◦C for 5 minutes. The resultant
cDNA (2.5μL) was added to 0.5μL1 0 m md N T P ,0 . 5 μL
polymerase (2 units), and 1μLo f1 0 μM the appropriate
primers, and the ﬁnal volume of the reaction mixture
was adjusted to 25μL. Polymerase chain reaction (PCR)
was performed for 35 cycles with each cycle consisting
of 45 seconds of denaturation at 94◦C, 45 seconds of
annealing at proper annealing temperature, and 1 minute
of extension at 72◦C. The primers used were as follows:
OCN (5 -TCT GAC AAA GCC TTC ATG TCC-3  and 5 -
AAA TAG TGA TAC CGT AGA TGC G-3 ), IGF-1 (5 -
GCT CTT CAG TTC GTG TGT GG-3  and 5 -TTG GGC-
A T GT C AG T GT G G - 3  ), BMP-2 (5 -CAT CCA GCC -
GAC CCT TG-3  and 5 -CTC TCC CAC TGA CTT GTG-
3 ), ALP (5 -GCC CTC TCC AAG ACA TAT A-3  and 5 -
CCA TGA TCA CGT CGA TAT CC-3 ), COL- (5 -TCT-
CCA CTC TTC TAG TTC CT-3  and 5 -TTG GGT CAT -
TTC CAC ATG C-3 ),β-actin(5 -GAC TAC CTC ATG A-
AG ATC CT-3  and 5 -CCA CAT CTG CTG GAA GGT -
GG-3 ), IL-4 (5 -TG GGT CTC AAC CCC CAG CTA GT-
3  and 5 -GCT CTT TAG GCT TTC CAG GAA GTC-3 ),
IL-6 (5 -ATG AAG TTC CTC TCT GCA AGA GAC T-
3  and 5 -CAC TAG GTT TGC CGA GTA GAT CTC-3 ),
and TGF-β (5 -TGG ACC GCA ACA ACG CCA TCT A-
TG CCA TCT ATG AGA AAA CC-3  and 5 -TGG AGC-
TGA AGC AAT AGT TGG TAT CCA GGG CT-3 ). The
reaction products were analyzed by electrophoresis on a 2%
agarosegelandvisualizedbyethidiumbromidestainingwith
ultraviolet light illumination. Gene expression levels were
analyzed by IMAGEQUANTE software and normalized with
β-actin. Real-time PCR was performed using an Applied
Biosystems 7500 Real-Time PCR System (Applied Biosys-
tems). The PCR mixture was prepared using SYBR green
Mastermix (Roche). The thermal cycling conditions were
10 minutes at 95◦C followed by 40 cycles of 95◦Cf o r1 5
seconds and 57◦C (OCN and IGF-1) for 20 seconds, with an
extension period at 72◦C for 40 seconds. Expression of each
gene was normalized to GAPDH mRNA content.
2.10. Animal Models. There were two diﬀerent sets for the
in vivo experiment. In the ﬁrst series of experiments, intact
female mice (without OVX surgery) were fed a normal
diet containing diﬀerent concentrations (0, 40, 200, and
1000mg/kg/day) of Dispo85E ad libitum for 5 days (n =
4 for each group). In the second set of experiments, we
used an OVX mouse model to mimic osteoporosis in
postmenopausal women. The mice were subjected to surgery
at day 0. Sham surgery was performed by identifying the
bilateral ovaries, and OVX was performed by removing the
bilateral ovaries. Mice (n = 10-11 for each group) were ini-
tially fed a normal diet containing diﬀerent concentrations
(0, 40, 200, and 1000mg/kg/day) of Dispo85E ad libitum.
Feeding began soon after OVX surgery and continued for
42 days. We identiﬁed OVX mice by conﬁrming uterus at-
rophy in OVX animals at the end of the experiment. At
the end of the experiment, all mice were sacriﬁced by
cervical dislocation. Bone marrow cells were then acquired
from the femur of each mouse. The drug’s eﬀect on
ALP activity, nodule formation, mRNA expression of the
osteoblast diﬀerentiation related genes in bone marrow cells,
histological change of the trabecular bone, trabecular bone
mineral density (tBMD), and bone tissue microarchitecture
were analyzed. To analyze the drug’s eﬀect on the gene
expression of bone marrow cells, we extracted total RNA
from bone marrow cells of the femora of the intact or OVX
mice after continuous feeding with Dispo85E and examined
expression through RT-PCR. To analyze the drug’s eﬀect4 Evidence-Based Complementary and Alternative Medicine
on the ALP activity of bone-marrow-derived cells isolated
from intact or OVX mice, the mice were sacriﬁced to isolate
the bone marrow cells after treatment with diﬀerent doses
of Dispo85E. The isolated bone marrow cells were seeded
in a 96-well microplate at 2.5 × 105/well and cultured in
osteogenic induction medium for 6 days without additional
Dispo85E treatment. After 6 days of culture, the ALP activity
for each cell lysate was assayed.
2.11. Histological Analysis of Trabecular Bone. Histomor-
phometric measurements of trabecular bone volume were
performed as described previously with minor modiﬁcations
[12]. In brief, femora were collected 42 days after the surgical
operation, ﬁxed in Bouin’s solution at 26◦C for 24 hours,
decalciﬁed in 14% EDTA, dehydrated in progressive con-
centrations of ethanol, cleared in xylene, and embedded in
paraﬃn. Five-micron-thick sections were cut and stained for
hematoxylin and eosin Y. Static parameters were measured
in the square, distal metaphysics of the femur within the
endosteal surfaces, excluding the epiphyseal growth plate,
and 1mm distal from the end of the calciﬁed cartilage.
Histomorphometric measurements of the bone volume/total
bone volume percentage (BV/TV, %) were performed at 40-
fold magniﬁcation.
2.12. Analysis of Trabecular Bone Microarchitecture. The
OVX mice were sacriﬁced 42 days after beginning the treat-
ment with Dispo85E. The femurs were aseptically removed,
cleansedofadherentsofttissues,anddepositedinatubewith
10% formalin. The trabecular bone microarchitecture of the
distal femoral metaphysis was scanned by microcomputed
tomography (μCT, Skyscan 1076) in the region of 0.6–
2.1mm from the growth plate. The X-ray source was
set at a voltage of 48kV and a current of 200μAa n d
ﬁlteredwitha0.5mmaluminumﬁlter.Thescanning angular
rotation was 180◦ with an angular step of 0.7◦. The voxel
size was isotropic and ﬁxed at 8.7μm. The trabecular bone
parameters were calculated using the Skyscan software CTan
(Skyscan). Morphometric indices of the trabecular bone
region were determined from the microtomographic data
sets using direct 3D morphometry. Trabecular bone vol-
ume (BV/TV; %), trabecular thickness (Tb.Th; mm), and
trabecular number (Tb.N; 1/mm) were calculated. The
volumetrictrabecularbonemineraldensity(tBMD)wasalso
determined by μCT scanning. tBMD was calculated in the
conforming volume of interest described previously for the
trabecular region.
2.13.StatisticalAnalysis. Allresultsareexpressedasthemean
and standard deviation (SD). The statistical signiﬁcance
was evaluated by one-way analysis of variance (ANOVA)
followed by Dunnett’s test. A level of P<. 05 was considered
statistically signiﬁcant.
3. Results
3.1. HPLC Analysis of Dispo85E. Dispo85E is a mixture ex-
tracted from the traditional botanical Dioscorea alata L. cv.
Phyto. This mixture contains both polar and nonpolar small
molecule ingredients. The-reverse phase HPLC analysis
showed the polar to semipolar ingredient ﬁngerprint of
Dispo85E, and the normal phase HPLC analysis showed the
nonpolar ingredient ﬁngerprint of Dispo85E (Figure 1).
3.2. Dispo85E Promotes Diﬀerentiation of Osteoblastic Cells
in Bone Marrow Culture. The ALP activity assay showed
that bone marrow cells treated with Dispo85E had a 1.5-
fold maximal increase in the activity of ALP (Figure 2(a)).
In the cell viability assay, there were no signiﬁcant dif-
ferences between the control and Dispo85E-treated groups
(Figure 2(b)). Furthermore, Dispo85E signiﬁcantly stimu-
lated mineralization of bone marrow cultures by alizarin red
staining (Figures 2(c) and 2(d)).
3.3. Dispo85E Promotes Osteoblastogenesis and Inhibits Adi-
pogenesis in the Mesenchymal Stem Cell Line C3H10T1/2.
The real-time PCR results showed that mRNA expression of
IGF-1, which could promote osteoblast diﬀerentiation and
bone formation, was signiﬁcantly increased after treatment
with Dispo85E (Figure 3(a)). OCN (an osteoblastic marker)
mRNA expression was signiﬁcantly increased by approx-
imately 2.5-fold after treatment with 1μg/mL Dispo85E
(Figure 3(b)). Concomitantly, we observed increased ALP
activity in C3H10T1/2 cells treated with Dispo85E (Figure
3(c)), which had no eﬀect on cell viability (Figure 3(d)).
TheeﬀectsofDispo85Eonadipocytediﬀerentiationwere
detected by oil red O staining (Figure 3(e))a n dq u a n t i ﬁ e d
by Nile red staining and ﬂow cytometry (FACS) anal-
ysis (Figure 3(f)). After 12 days in adipogenic medium,
C3H10T1/2 cells showed an abundance of oil-red-O-
stained lipid droplets (Figure 3(e)). Dispo85E resulted in
a dose-dependent decrease in cellular lipid accumulation
(Figure 3(e)). Using ﬂow cytometry and Nile red staining,
the percentage of adipocytes were calculated based on
the number of stained cells. After culture in adipogenic
medium for 16 days, 63.6% of the cells were calculated to
be adipocytes (Figure 3(f)). After treatment with 1, 10, or
100μg/mL Dispo85E, the percentages of adipocytes were
54.1%, 47.3%, and 49.8%, respectively (Figure 3(f)).
3.4. Dispo85E Promotes Osteoblastogenesis in Intact Mice
(without OVX Surgery)
Gene Expression. We used the expression level of β-actin
mRNA as a house-keeping gene. Compared to the expression
of β-actin mRNA, the relative levels of BMP-2, TGF-β,
a n dI L - 4m R N Aw e r eh i g h e ri nb o n em a r r o wc e l l sf r o m
Dispo85E-treated mice than those from untreated controls
(Figure 4(a)).
Alkaline Phosphate Activity Assay. We measured the speciﬁc
activityofALPofbonemarrowcellsisolatedfromDispo85E-
fed or control mice for 5 days. The ALP activity was signifi-
cantly higher in all Dispo85E-treated groups (Figure 4(b)).
Dispo85E at a dose of 1000mg/kg created up to a 3-fold
enhancement compared to the control group.Evidence-Based Complementary and Alternative Medicine 5
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Figure 1: HPLC analysis of Dispo85E. (a) Reverse-phase HPLC proﬁle. Column: Mightysil RP-18 (4.6 × 250mm, 5mm); mobile phase:
methanol-water (methanol: 10–100% in 120 minutes); ﬂow rate: 0.8mL/minute; detection wavelength: 254nm. (b) Normal-phase HPLC
proﬁle. Column: Cosmosil 5SL-II (4.6 × 250mm, 5mm); mobile phase: 100%–98% DCM in MeOH (0–15 minutes), 98%–95% DCM
(15–25 minutes), 95%–90% DCM (25–35 minutes), 90%–80% DCM (35–45 minutes), and 80%–70% DCM (45–55 minutes); ﬂow rate:
0.8mL/minute; detection wavelength: 254nm.
Table 1: Eﬀects of Dispo85E on tBMD and morphometric parameters of distal femur in OVX model.
Parameters Sham OVX + Dispo85E (mg/kg/day)
0 40 200 1000
tBMD (g/cm3) 0.088 ± 0.003 0.054 ± 0.008∗ 0.083 ± 0.003‡ 0.063 ± 0.009∗ 0.081 ± 0.006‡
BV/TV (%) 4.34 ± 0.36 2.56 ± 0.44∗ 4.17 ± 0.29† 3.50 ± 0.69 4.11 ± 0.39†
Tb.Th (μm) 60.7 ± 1.03 59.30 ± 0.71 64.36 ± 2.25 63.15 ± 2.70 63.03 ± 2.26
Tb.N (1/mm) 0.72 ± 0.06 0.43 ± 0.07∗ 0.65 ± 0.04† 0.55 ± 0.10 0.66 ± 0.06†
Values are expressed as mean ± SD; n = 5-6/group. tBMD: trabecular bone mineral density; BV/TV: bone volume fraction; Tb.Th: trabecular thickness; Tb.N:
trabecular number.
∗P<. 05 compared with the sham operated group;
†P<. 05 compared with OVX control group;
‡P<. 01 compared with OVX control group.
Nodule Formation Assay. To evaluate whether Dispo85E
enhanced bone mineralization, we used alizarin red staining
to visualize nodule formation in bone marrow cultures
(Figure 4(c)). The proportional area of alizarin-red-positive
staining in the Dispo85E-treated group was larger than
that in the untreated group in a dose-dependent manner
(Figure 4(d)).Comparedwiththecontrolgroup,1000mg/kg
Dispo85Eshowedthestrongestenhancement,witheﬀectsup
to 3.4-fold above controls (Figure 4(d)).
3.5. Dispo85E Promotes Osteoblastogenesis in OVX-Induced
Osteoporotic Mice
Gene Expression. Bone morphogenetic protein-2 (BMP-2),
transforming growth factor-β (TGF-β), and interleukin-4
(IL-4) are positively related to the proliferation or diﬀerenti-
ationofbonemarrowcellstowardanosteoblastlineage.ALP,
collagen I (COL-I), and osteocalcin (OCN) are widely used
as bone formation or osteoblastic cells markers. Interleukin-
6 (IL-6) is a bone resorption marker. When compared to β-
actin, the relative levels of BMP-2, TGF-β, IL-4, ALP, COL-
I, and OCN mRNA were higher in bone marrow cells from
Dispo85E-treated mice than in untreated mice. Conversely,
the bone resorption marker gene IL-6 was decreased after
treatment with Dispo85E (Figure 5(a)).
Alkaline Phosphate Activity Assay. The ALP activity of all
Dispo85E-treated groups was signiﬁcantly higher than that
of the untreated group (Figure 5(b)).
Nodule Formation Assay. Groups treated with 200 and
1000mg/kg/day Dispo85E showed enhanced bone mass mi-
neralization compared to the untreated group (Figures 5(c)
and 5(d)).
HistologicalAnalysisofTrabecularBone. Histologicalanalysis
of the trabecular bone was performed in the OVX mouse
model. The animal data in the sham-operated positive
control group showed a signiﬁcant increase in the trabecular
bone volume/total bone volume percentage (BV/TV, %)
compared to the vehicle control group. There was a signiﬁ-
cantincreaseinBV/TVforalldosagegroupscomparedtothe
vehicle control group (0mg/kg/day). Moreover, the increase
was positively correlated with dose level. The histomorpho-
metric analysis in the OVX model revealed increases in
the osteoid volume in a dose-dependent manner (Figure 6),6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Dispo85E stimulates osteoblastogenesis in bone-marrow-derived cells. Primary bone-marrow-derived cells were cultured with
osteogenic medium and treated with Dispo85E at the indicated concentrations. At PID 6, (a) cellular alkaline phosphatase (ALP) activity
and (b) the eﬀect of Dispo85E on cell viability were measured (n = 4). (c) At PID 16, cells were stained with alizarin red S, and (d) the
mineralized area was quantiﬁed by extracting alizarin red S staining with 10% cetylpyridinium chloride (CPC) and measuring the OD of the
extract at 550nm (n = 3). ∗∗Indicates signiﬁcant diﬀerence from control group at P<. 01; ∗Indicates signiﬁcance at P<. 05.
suggesting that Dispo85E ameliorates the decreasing trabec-
ulation of the bone marrow spaces in osteoporotic mice.
Analysis of Trabecular Bone Microarchitecture. The eﬀects of
Dispo85E on trabecular bone microarchitecture and trabec-
ular BMD of the distal femur in OVX mice were assessed by
ex vivo μCT analysis. Quantiﬁcation of the trabecular bone
changes in the distal femoral metaphysis is shown in Table 1.
Compared with the sham-operated animals, the OVX con-
trol group showed a signiﬁcant decrease in trabecular bone
mineral density (tBMD), trabecular bone volume fraction
(BV/TV),andtrabecularnumber(Tb.N).Both40mg/kg/day
and 1000mg/kg/day of Dispo85E signiﬁcantly improved
variousμCT bone parameters, including tBMD, BV/TV, and
Tb.N compared to the OVX control group, but trabecular
thickness (Tb.Th) was not signiﬁcantly altered compared to
the OVX control (Table 1).
4. Discussion
Several drugs have been reported to be eﬀective in treating
osteoporosis. However, most of these drugs are inhibitors
of osteoclast-mediated bone resorption and present many
detrimental side eﬀects [19]. For example, estrogen replace-
ment therapy has been demonstrated to prevent bone
loss in postmenopausal women [20]. However, despite the
beneﬁts of estrogen, many studies have also shown that
estrogen would increase the incidence of ovarian cancer and
breast cancer [7, 8]. Furthermore, epidemiological reports
have shown that hormone replacement therapy (HRT) is
associated with increases in the incidence rates of breast
cancer, heart attacks, stroke, and blood clot formation. Such
studies have prompted the US FDA to issue safety warnings
andtosuggesttheavoidanceofHRTasageneralpreventative
osteoporosistherapy[20,21].Ontheotherhand,Teitelbaum
highlighted that compounds that can stimulate new boneEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: Dispo85E stimulates osteoblastogenesis and inhibits adipogenesis in the mesenchymal stem cell line C3H10T1/2. C3H10T1/2
cells were grown to conﬂuence in a standard medium. One day after conﬂuence, the medium was replaced with a permissive
osteogenic/adipogenic medium containing Dispo85E at the indicated concentrations. At PID 12, the mRNA level of IGF-1 (a) and OCN
(b) was analyzed by real-time PCR (n = 3). (c) ALP activity and (d) the eﬀect of Dispo85E on cell viability were measured (n = 4). (e) Cells
were induced with adipogenic medium and treated with drugs. At PID 12, the cells were stained with oil red O to assess lipid accumulation
(magniﬁcation, 200-fold). (f) After 16 days of culture in adipogenic medium, cells were harvested, ﬁxed, and stained with Nile red solution.
PercentageofNile-red-stainedcellsinthetotalpopulationofeachsamplewerequantiﬁedwithFACScanﬂowcytometry(n = 3). ∗∗Indicates
signiﬁcant diﬀerence from control group at P<. 01; ∗Indicates signiﬁcance at P<. 05.8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Dispo85E stimulates osteoblastogenesis in bone-marrow-derived cells isolated from intact mice. C57BL/6 mice were fed with
0mg/kg/day (vehicle control), 40mg/kg/day, 200mg/kg/day, or 1000mg/kg/day Dispo85E for 5 days. (a) Expression of mRNA for diﬀerent
bone regulatory factors in mouse bone-marrow-derived cells was evaluated by RT-PCR. The ampliﬁed fragments were visualized on
ethidium-bromide-stained agarose gels. (b) Cellular ALP activity and (c) nodule formation assay were performed as described in Section 2.
Cells were stained with alizarin red S for osteoblasts and (d) the mineralized area was quantiﬁed using Meta Image software. ∗∗Indicates
signiﬁcant diﬀerence from control group at P<. 01. n = 4f o re a c hg r o u p .
formation may oﬀer safe and clinically eﬀective prevention
and reversal of osteoporosis [22].
Bone marrow cells have long been recognized as the
source of osteoprogenitor cells [23]. Thus, we applied a cul-
ture model of primary bone marrow cells to evaluate the
eﬀect of Dispo85E on the diﬀerentiation of osteoblasts. In-
triguingly, our observations of ALP activity and mineraliza-
tion suggested that Dispo85E possessed higher eﬃcacy in
promoting osteoblast diﬀerentiation. In this assay, we meas-
ured cell viability and found no signiﬁcant diﬀerence be-
tween the control and treated groups. Therefore, we suggest
thatDispo85Edoesnotinﬂuencetheproliferationofstromal
cells in vitro.
Recently,ithasbeensuggestedthatosteoporosisiscaused
by an increased ratio of adipocytes to osteoblasts and not
by an imbalance between osteoclasts and osteoblasts alone
[24]. Indeed, an increase in adipogenesis in bone marrow
associated with osteoporosis is well known clinically [25].
Other studies have also demonstrated that increases in the
number of marrow adipocytes caused bone loss in osteo-
porosis animal models, such as in ovariectomized or
glucocorticoid-treated animals [26, 27]. It was reported that
the number of osteoblasts correlated negatively with the
number of adipocytes, which suggested that an inverse rela-
tionship between osteogenic and adipogenic diﬀerentiation
exists [28, 29].
It is known that multipotent mesenchymal stem cells
(MSCs) from bone marrow stroma can diﬀerentiate into
variouscells,includingosteoblastsandadipocytes[30,31].A
shift in diﬀerentiation and survival rates from an osteoblastic
to adipocytic lineage can lead to an altered ratio of fat to
bone cells and, ultimately, an alteration in bone mass [31].
Thus, it has been suggested that targeting regulatory factors
to direct the fate of mesenchymal cells toward osteoblastsEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: Dispo85E stimulates osteoblastogenesis in bone-marrow-derived cells isolated from OVX mice. C57BL/6 mice were sham or OVX.
TheOVXmicewerefed0mg/kg/day(vehiclecontrol),40mg/kg/day,200mg/kg/day,or1000mg/kg/dayDispo85Efor42days.(a)Expression
of the mRNA for diﬀerent bone regulatory factors and osteoblastic markers in OVX mouse bone-marrow-derived cells was evaluated by RT-
PCR. (b) Cellular ALP activity and (c) nodule formation assay were performed as described in Section 2.C e l l sw e r es t a i n e dw i t hA l i z a r i n
red S for osteoblasts, and (d) the mineralized area was quantiﬁed by extracting alizarin red S staining with 10% CPC and measuring the OD
of the extract at 550nm. ∗∗Indicates signiﬁcant diﬀerence from OVX mice at P<. 01; ∗Indicates signiﬁcance at P<. 05. n =10-11 for each
group.
may provide novel therapeutic approaches for osteoporosis
[32]. In this study, we used the C3H10T1/2 cell line, which
maintains the diﬀerentiating characteristics of mesenchymal
stem cells [33], to evaluate the eﬀect of Dispo85E on the
osteogenesis/adipogenesis balance. Our in vitro data showed
that Dispo85E could promote the diﬀerentiation of mes-
enchymal stem cells into the osteoblastic lineage and reduce
adipogenic diﬀerentiation. Recently, it has been reported
that the number of adipocytes in bone marrow correlated
inversely with the hematopoietic activity of the marrow [34].
We also suggest that the antiadipogenic eﬀect of Dispo85E
might have the potential for use in some hematopoietic
disorders.
Insulin-like growth factor I (IGF-I) is known as an
important factor produced by osteoblasts to regulate bone
formation and remodeling [35]. It can induce human adult
mesenchymal stem cells (hMSCs) to diﬀerentiate into an
osteogenic lineage [36]. Some clinical data show that IGF-
I was lower in women with osteoporosis than in women
with normal bone mineral density (BMD) [37]. In addition,
low serum IGF-1 can contribute to reduced BMD, reduced
osteoblast diﬀerentiation, and increased the numbers of
adipocytes in bone [38]. Real-time PCR showed that
Dispo85E increased IGF-1 mRNA expression in C3H10T1/2
cells. Thus, we suggest that one way Dispo85E regulates the
diﬀerentiation of MSCs is through IGF-1 upregulation.
To evaluate whether Dispo85E enhanced bone formation
in vivo, we used two kinds of animal models. In the intact
mouse model, we evaluated the ability of Dispo85E to
promote osteoblastogenesis under physiological conditions.
PCR showed that Dispo85E increased BMP-2, TGF-β,a n d
IL-4 gene expression in bone marrow cells. BMP-2 has been10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀect of Dispo85E on trabecular bone volume in OVX mouse model. C57BL/6 mice were sham operated (a) or OVX. The OVX
mice were fed 0mg/kg/day (vehicle control) (b), 40mg/kg/day (c), 200mg/kg/day (d), or 1000mg/kg/day (e) Dispo85E for 42 days. The
femora were collected 42 days after the operation, and the sections of distal femoral metaphysis were stained with Hematoxylin-eosin.
Arrow indicates the trabecular bone. (f) Histomorphometric measurements of bone volume/total bone volume percentage (BV/TV, %) were
performed. Measurement was performed at a magniﬁcation of 40-fold. ∗∗Indicates signiﬁcant diﬀerence from OVX mice at P<. 01. n = 5
for each group.
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Figure 7: Dispo85E promotes bone formation by driving diﬀerentiation of mesenchymal stem cells into osteoblasts rather than adipocytes
and ameliorates osteoporosis in the mouse model.
known to stimulate osteoblastic maturation and collagen
synthesis in osteoblastic cells [39], TGF-β has been reported
to stimulate the proliferation of osteoblast precursors and
increase the pool of committed osteoblasts [40], and IL-4
is a potent inhibitor of bone resorption [41]. In addition,
the results of the ALP activity assay and alizarin red staining
for mineralization of bone marrow showed that Dispo85E
promotes osteoblast diﬀerentiation in healthy animals.
Next, we used an OVX mouse model to mimic the osteo-
porosis seen in postmenopausal women. After 6 weeks of
treatment, Dispo85E promoted osteoblastogenesis without
a signiﬁcant eﬀect on uterine weight (data not shown).
This result diﬀers from the previously observed restorative
eﬀects of estrogen replacement [42]. Therefore, we suggest
that Dispo85E might act via a diﬀerent mechanism from
estrogen, which aﬀects the uterus as well as bone. In this
animal study, we analyzed bone marrow cells after 42 days
of OVX. Our results showed that ALP activity in bone
marrow cells (cultured in osteogenic induction medium for
6dayswithoutadditionalDispo85Etreatment)ofDispo85E-
treated groups was higher than that of the OVX control
group. These data indicated that Dispo85E-treated groupsEvidence-Based Complementary and Alternative Medicine 11
contained more osteoprogenitor cells than the untreated
group in the OVX mice model.
Previous studies have clearly shown a reduction of tra-
becular bone volume during aging and in osteoporosis pa-
tients [43]. In our study, histological analysis of the femora
harvested from OVX mice showed an empty bone mar-
row space in the trabecular bone. After administration of
Dispo85E for 42 days, the trabecular bone volume was
increased. Additionally, the μCT data conﬁrmed that
40mg/kg/day and 1000mg/kg/day of Dispo85E could sig-
niﬁcantly ameliorate the deterioration of both tBMD and
trabecular microarchitectural parameters in OVX mice. The
200mg/kg/day group also showed better indices than the
untreated group, although it did not reach statistical signif-
icance. This may be due to the limited number of animals
in our study or inconsistencies in the mixture chemistry of
the Dispo85E extract. These data indicated that Dispo85E
promotes osteoblast diﬀerentiation and bone formation in
an osteopenic setting without side eﬀects on the uterus.
Recent studies have shown that natural products have
potential as alternative approaches to prevent and ameliorate
osteoporosis through diﬀerent mechanisms. For example,
Xie et al. reported that Herba epimedii (HEP) extract can
eﬀectively suppress the OVX-induced increase in bone turn-
over, possibly by both an increase in osteoblastic activities
and a decrease in osteoclastogenesis [44]. Ho et al. reported
that Flemingia macrophylla extract can ameliorate experi-
mental osteoporosis in OVX rats through inhibition of bone
resorption [45]. Hidaka et al. reported that royal jelly (RJ)
can prevent osteoporosis by enhancing intestinal calcium
absorption[46].Inthesestudies,mostofthedrugshavebeen
reported to achieve improvement in osteoporosis by regulat-
ing the balance between osteoblasts and osteoclasts. Unlike
these drugs, our study has shown that Dispo85E can drive
the lineage-speciﬁc diﬀerentiation of bone marrow stromal
cells to diﬀerentiate into osteoblasts rather than adipocytes.
Furthermore,ourdatashowedthatDispo85Ecouldpromote
the diﬀerentiation and maturation of osteoblasts in both
intact and OVX mice. Therefore, we suggest that Dispo85E
not only can decrease the process of bone loss but also can
regulate the balance between osteoblasts and adipocytes to
promote bone formation.
Based on these ﬁndings, we conclude that Dispo85E
regulates mesenchymal stem cell diﬀerentiation into an
osteogenic lineage rather than an adipogenic lineage and
ameliorates osteoporosis in a mouse model (Figure 7). Our
data suggest that Dispo85E induces mesenchymal stem cell
diﬀerentiationandholdspromiseasanoveltherapeuticdrug
for the treatment of osteoporosis.
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